Australia's Lumos Diagnostic soars on tie-up with US Henry Schein

Lumos Diagnostics Holdings

16/08/2023 03:44

** Shares of Lumos Diagnostic Holdings  LDX.AX  jump as much
as 29.6% to A$0.092, their biggest intraday pct increase since
July 4
    **  Diagnostics solutions provider signs agreement with
Henry Schein B.V., part of U.S.-based health care products
distributor Henry Schein Inc  HSIC.O , for the FebriDx
point-of-care (POC) test
    ** Agreement expands distribution of FebriDx, a rapid POC
test to differentiate viral and bacterial acute respiratory
infection, through Henry Schein's medical business in the
Netherlands
    ** Stock hits highest level since July 10
    ** More than 50 mln shares changed hands, versus 30-day
average of ~27.9 mln shares 
    ** As of last close, stock up ~47.9% this year
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))